JPWO2020065409A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020065409A5 JPWO2020065409A5 JP2021517801A JP2021517801A JPWO2020065409A5 JP WO2020065409 A5 JPWO2020065409 A5 JP WO2020065409A5 JP 2021517801 A JP2021517801 A JP 2021517801A JP 2021517801 A JP2021517801 A JP 2021517801A JP WO2020065409 A5 JPWO2020065409 A5 JP WO2020065409A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- seq
- positions
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 47
- 101150013553 CD40 gene Proteins 0.000 claims 19
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 19
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 16
- 230000035772 mutation Effects 0.000 claims 13
- 239000013598 vector Substances 0.000 claims 10
- 230000037430 deletion Effects 0.000 claims 8
- 238000012217 deletion Methods 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 229940122551 CD40 antagonist Drugs 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018010828 | 2018-09-28 | ||
| CNPCT/CN2018/010828 | 2018-09-28 | ||
| PCT/IB2019/001135 WO2020065409A2 (en) | 2018-09-28 | 2019-09-27 | Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022503961A JP2022503961A (ja) | 2022-01-12 |
| JP2022503961A5 JP2022503961A5 (https=) | 2022-10-04 |
| JPWO2020065409A5 true JPWO2020065409A5 (https=) | 2022-10-04 |
| JP7626698B2 JP7626698B2 (ja) | 2025-02-04 |
Family
ID=69950020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517801A Active JP7626698B2 (ja) | 2018-09-28 | 2019-09-27 | 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP7626698B2 (https=) |
| AU (1) | AU2019349874A1 (https=) |
| CA (1) | CA3114567A1 (https=) |
| WO (1) | WO2020065409A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112512572B (zh) | 2018-04-20 | 2024-12-10 | 礼进生物医药科技（上海）有限公司 | 抗cd40抗体及其用途 |
| CR20230119A (es) * | 2020-08-07 | 2023-05-16 | Genentech Inc | Proteínas de fusión del ligando para flt3 y métodos de uso |
| JP2024500945A (ja) * | 2020-12-23 | 2024-01-10 | マクファーレン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッド | ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法 |
| WO2024126289A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection |
| WO2024126294A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection |
| WO2024126293A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| BRPI0417266B8 (pt) * | 2003-12-25 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | anticorpo monoclonal, seu uso e composição farmacêutica |
| EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2016177771A1 (en) * | 2015-05-04 | 2016-11-10 | Apogenix Ag | Single-chain cd40-receptor agonist proteins |
| JP7497953B2 (ja) * | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| AU2016285920A1 (en) * | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
| ES2985566T3 (es) * | 2016-03-04 | 2024-11-06 | Univ Rockefeller | Anticuerpos contra CD40 con actividad agonista mejorada |
-
2019
- 2019-09-27 JP JP2021517801A patent/JP7626698B2/ja active Active
- 2019-09-27 CA CA3114567A patent/CA3114567A1/en active Pending
- 2019-09-27 WO PCT/IB2019/001135 patent/WO2020065409A2/en not_active Ceased
- 2019-09-27 AU AU2019349874A patent/AU2019349874A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022503961A5 (https=) | ||
| JP7773528B2 (ja) | 抗ｃｄ２８組成物 | |
| JP7809372B2 (ja) | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 | |
| JP7612596B2 (ja) | Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体 | |
| RU2767357C2 (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| CA2867020C (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| AU2010303142B2 (en) | Bispecific death receptor agonistic antibodies | |
| JP2021521275A5 (https=) | ||
| RU2013155029A (ru) | Терапевтические антитела | |
| JP2019500892A5 (https=) | ||
| KR20150130349A (ko) | 4가 이중특이적 항체 | |
| US20230052369A1 (en) | Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof | |
| CN110831979A (zh) | 肿瘤抗原递呈诱导物构建体及其用途 | |
| CA3130628A1 (en) | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders | |
| JPWO2019226973A5 (https=) | ||
| JPWO2019198051A5 (https=) | ||
| CN116583300A (zh) | 多特异性抗原结合蛋白 | |
| JPWO2021019389A5 (https=) | ||
| US20250043001A1 (en) | Anti-cd28 compositions | |
| JP7836088B2 (ja) | ＦｃγＲＩＩＢ親和性が増強された抗体Ｆｃ領域 | |
| JPWO2020065409A5 (https=) | ||
| JPWO2022212876A5 (https=) | ||
| IL293640A (en) | CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors | |
| JPWO2021181366A5 (https=) | ||
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof |